Statistics in Medicine · 2024 · 10 citations · 12 references
Public HealthBiostatisticsBayesian BiostatisticsClinical EpidemiologySurvival AnalysisLongitudinal Data AnalysisRandom Effects ModelingRepeated Measures For Categorical OutcomesSurvival ModelingBayesian Joint Longitudinal-survival ModelsContinuous-time ModelsGeneralized Linear Mixed-effects ModelsLinear Mixed ModelsLongitudinal Data ModelingLongitudinal Mixed ModelsMixed Linear Models
Longitudinal data from clinical trials are commonly analyzed using mixed models for repeated measures (MMRM) when the time variable is categorical or linear mixed-effects models (ie, random effects model) when the time variable is continuous. In these models, statistical inference is typically based on the absolute difference in the adjusted mean change (for categorical time) or the rate of change (for continuous time). Previously, we proposed a novel approach: modeling the percentage reduction in disease progression associated with the treatment relative to the placebo decline using proportional models. This concept of proportionality provides an innovative and flexible method for simultaneously modeling different cohorts, multivariate endpoints, and jointly modeling continuous and survival endpoints. Through simulated data, we demonstrate the implementation of these models using SAS procedures in both frequentist and Bayesian approaches. Additionally, we introduce a novel method for implementing MMRM models (ie, analysis of response profile) using the nlmixed procedure.
12
Lecanemab in Early Alzheimer’s Disease
Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 5.2K citations · Full text
Donanemab in Early Symptomatic Alzheimer Disease
John R. Sims, Jennifer A. Zimmer, Cynthia Evans et al. · JAMA · 2023 · 2.6K citations · Full text
Medicine, Neurology, Neuroscience +17
Donanemab in Early Alzheimer’s Disease
Mark A. Mintun, Albert Lo, Cynthia Evans et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Stephen Salloway, Martin R. Farlow, Eric McDade et al. · Nature Medicine · 2021 · 365 citations · Full text
Medicine, Neurology, Pharmacotherapy +12